NCT00268840

The Efficacy and Safety of Gemcitabine in Combination With Docetaxel to Treat Pancreatic or Biliary Cancer

National Trial Phase II to Study the Combination of Gemcitabine and Docetaxel in Patients With Locally Advanced or Metastatic Pancreatic or Biliary Adenocarcinoma That Cannot be Removed by Surgery

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 45 (actual)
• Sponsor: ARCAGY/ GINECO GROUP · Academic / Other
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the efficacy of combination therapy with gemcitabine and docetaxelin in patients with locally advanced or metastatic pancreatic or biliary adenocarcinoma.

Detailed description

Try a new drug association on this advanced cancer

Conditions

• Pancreatic Neoplasms
• Biliary Tract Neoplasms

Interventions

Type	Name	Description
DRUG	Docetaxel	Docetaxel 50 mg/m2 ou 35 mg/m² (suivant le bilan hépatique) à J1 et J15 toutes les 4 semaines
DRUG	Gemcitabine	Gemcitabine 1200 mg/m2 à J1 et J15 toutes les 4 semaines

Timeline

• Start date: 2001-08-01
• Primary completion: 2006-02-01
• Completion: 2006-02-01
• First posted: 2005-12-23
• Last updated: 2011-06-30

Locations

1 site across 1 country: France